Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2020
FDA approves Concord Biotech’s Tacrolimus application
Concord Biotech received approval from the US Food and Drug Administration for its abbreviated new drug application for Tacrolimus capsules.
2020
Lupin launches generic mycophenolic acid tablets
Lupin announced the launch of Mycophenolic Acid Delayed-Release Tablets USP in 180 mg and 360 mg strengths, a generic equivalent of Novartis Pharmaceuticals Corporation's Myfortic delayed-release tablets. Concord Biotech, Lupin's alliance partner, had earlier received U.S. FDA approval.